

Reference section 1

Patient survival



table i.1 · 549

incident patient counts: ESRD patients

by age, gender, race, ethnicity, & primary diagnosis

table i.2 · 550

one-year survival probabilities: incident ESRD patients

from day 91 to one year + 90 days, by age, gender, race, ethnicity, & primary diagnosis

table i.3 · 551

two-year survival probabilities: incident ESRD patients

from day 91 to two years + 90 days, by age, gender, race, ethnicity, & primary diagnosis

table i.4 · 552

five-year survival probabilities: incident ESRD patients

from day 91 to five years + 90 days, by age, gender, race, ethnicity, & primary diagnosis

table i.5 · 553

ten-year survival probabilities: incident ESRD patients

from day 91 to ten years + 90 days, by age, gender, race, & primary diagnosis

table i.6 · 554

incident patient counts: ESRD patients age 65 & over

patients age 65 & over on day 1, by age, gender, race, ethnicity, & primary diagnosis

table i.7 · 555

one-year survival probabilities: incident ESRD patients age 65 & over

from day 1 to one year, by age, gender, race, ethnicity, & primary diagnosis

table i.8 · 556

two-year survival probabilities: incident ESRD patients age 65 & over

from day 1 to two years, by age, gender, race, ethnicity, & primary diagnosis

table i.9 · 557

five-year survival probabilities: incident ESRD patients age 65 & over

from day 1 to five years, by age, gender, race, ethnicity, & primary diagnosis

table i.10 · 558

ten-year survival probabilities: incident ESRD patients age 65 & over

from day 1 to ten years, by age, gender, race, ethnicity, & primary diagnosis

table i.11 · 559

incident patient counts: dialysis patients

dialysis patients alive on day 91, by age, gender, race, ethnicity, & primary diagnosis

table i.12 · 560

one-year survival probabilities: incident dialysis patients

censored at transplant, from day 91 to one year + 90 days, by age, gender, race, ethnicity, & primary diagnosis

table i.13 · 561

two-year survival probabilities: incident dialysis patients

censored at transplant, from day 91 to two years + 90 days, by age, gender, race, ethnicity, & primary diagnosis

table i.14 · 562

five-year survival probabilities: incident dialysis patients

censored at transplant, from day 91 to five years + 90 days, by age, gender, race, ethnicity, & primary diagnosis

table i.15 · 563

ten-year survival probabilities: incident dialysis patients

censored at transplant, from day 91 to ten years + 90 days, by age, gender, race, & primary diagnosis



Table I.1
Incident Patient Counts: ESRD Patients
by age, gender, race, ethnicity, & primary diagnosis

	1980	1981	1982	1983	1984	1985	1986	1987	1988	1989	1990	1991	1992	1993	1994	1995	1996	1997	1998	1999	2000	2001
0-4	48	64	96	109	104	127	128	134	135	143	127	171	149	181	142	169	178	171	166	176	195	204
5-9	94	91	104	91	107	100	121	111	100	127	130	125	129	135	162	152	148	133	137	162	156	150
10-14	178	185	220	211	223	212	204	215	221	200	217	240	241	245	259	277	277	281	273	305	317	315
15-19	424	465	455	441	419	428	444	463	502	515	500	487	531	533	524	572	591	537	543	606	582	592
20-29	1,484	1,643	1,858	1,796	1,936	2,013	2,088	2,097	2,286	2,475	2,512	2,560	2,691	2,764	2,740	2,643	2,689	2,619	2,720	2,651	2,671	2,697
30-39	2,131	2,411	2,668	2,778	2,974	3,169	3,502	3,614	4,061	4,408	4,602	4,887	5,254	5,348	5,696	5,669	5,737	5,685	5,711	5,875	5,711	5,642
40-49	2,340	2,644	2,787	3,107	3,241	3,537	3,810	4,273	4,749	5,399	5,912	6,678	7,211	7,642	8,157	8,787	9,440	9,421	10,216	10,433	10,718	10,709
50-59	3,541	4,169	4,486	4,590	4,858	5,176	5,494	5,912	6,694	7,246	7,782	8,459	9,462	9,965	11,263	11,582	12,238	13,313	14,475	15,569	16,097	16,894
60-64	1,974	2,277	2,600	3,009	3,309	3,641	3,787	4,310	4,675	5,137	5,585	6,189	6,535	6,845	7,289	7,625	8,020	8,443	8,883	9,160	9,446	9,733
65-69	1,959	2,010	2,300	3,054	3,125	3,526	4,054	4,634	5,167	5,956	6,632	7,374	7,967	8,285	8,891	8,933	9,718	10,019	10,297	10,424	10,509	10,745
70-79	2,163	2,360	2,910	4,151	4,291	5,003	5,755	6,608	7,261	8,606	9,613	11,303	12,629	13,264	14,850	15,270	17,236	18,393	19,411	20,609	21,044	21,145
80+	359	390	542	842	908	1,129	1,380	1,613	1,943	2,413	2,791	3,261	3,840	4,149	4,708	5,113	6,105	6,918	7,606	8,580	9,251	9,645
Male	9,319	10,334	11,568	13,245	14,087	15,218	16,822	18,361	20,285	22,979	24,945	27,631	29,872	31,622	34,176	35,188	38,597	40,441	42,780	45,226	46,434	47,596
Female	7,376	8,375	9,458	10,934	11,408	12,843	13,945	15,623	17,509	19,646	21,458	24,103	26,767	27,734	30,505	31,604	33,780	35,492	37,658	39,324	40,263	40,875
White	10,649	12,195	14,262	15,922	16,934	18,650	20,588	22,506	24,780	27,913	30,541	33,992	36,888	38,345	41,509	41,890	45,711	48,477	50,961	54,339	56,035	56,915
Black	5,414	5,849	6,102	7,402	7,603	8,329	8,971	10,114	11,430	13,133	13,979	15,633	17,340	18,319	19,962	20,701	22,216	22,834	24,313	24,864	25,001	25,716
Other race	632	665	662	855	958	1,082	1,208	1,364	1,584	1,579	1,883	2,109	2,411	2,692	3,210	4,201	4,450	4,622	5,164	5,347	5,661	5,840
†Hispanic																				8,434	9,979	10,684
†Non-Hispanic																				63,943	67,307	71,249
Diabetes	2,528	3,689	4,863	5,651	6,789	7,827	9,011	10,226	11,662	14,132	16,065	18,437	20,592	21,806	24,598	27,643	31,324	33,488	35,440	37,497	39,036	40,117
Hypertension	2,826	4,034	5,148	5,702	6,336	7,252	7,918	9,077	10,467	12,068	13,322	14,726	16,437	16,979	18,462	17,204	18,713	20,110	20,851	22,161	22,494	23,232
Glomerulonephritis	2,423	3,081	3,687	3,953	4,202	4,427	4,467	4,909	5,218	5,521	5,907	6,244	6,497	6,696	7,180	7,594	8,033	7,764	8,329	8,142	7,866	7,752
Cystic kidney	710	878	999	1,006	1,036	1,082	1,182	1,216	1,248	1,238	1,372	1,475	1,518	1,603	1,595	1,850	1,838	1,900	2,076	2,137	2,153	2,192
Other urologic	397	508	512	583	602	733	718	705	767	801	823	938	1,017	900	868	1,146	1,399	1,353	1,390	1,542	1,504	1,500
Other cause	1,909	2,491	3,166	3,356	3,473	3,772	4,037	4,224	4,372	4,950	4,873	5,317	5,702	5,865	6,477	7,852	7,845	8,077	8,795	9,139	9,417	9,571
Unknown cause	1,659	1,935	1,814	1,971	2,113	2,220	2,642	2,966	3,139	3,246	3,462	3,995	4,411	4,809	5,103	3,141	2,854	2,874	3,080	3,228	3,476	3,562
Missing cause	4,243	2,093	837	1,957	944	748	792	661	921	669	579	602	465	698	398	362	371	367	477	704	751	545
All	16,695	18,709	21,026	24,179	25,495	28,061	30,767	33,984	37,794	42,625	46,403	51,734	56,639	59,356	64,681	66,792	72,377	75,933	80,438	84,550	86,697	88,471

The incident cohorts are determined at the time of ESRD initiation with the 60-day stable modality rule & the 90-day rule. The age of the incident patient is determined as of the date of ESRD initiation. Patients of unknown age, gender, & age >110 are excluded. Includes U.S. & territories; no unknown or foreign states. †CMS began collecting Hispanic ethnicity data in April 1995; cells for years prior to 1996 have therefore been left blank.



Table 1.2
One-year Survival Probabilities: Incident ESRD Patients
from day 91 to one year + 90 days, by age, gender, race, ethnicity, & primary diagnosis

UNADJUSTED	1980	1981	1982	1983	1984	1985	1986	1987	1988	1989	1990	1991	1992	1993	1994	1995	1996	1997	1998	1999	2000	2001
0-4	93.7	92.2	89.6	89.9	87.5	90.6	93.0	91.0	82.2	85.3	85.8	87.1	91.9	90.1	93.0	88.8	91.6	90.1	88.6	86.9	84.1	89.4
5-9	93.6	96.7	95.2	97.8	95.3	95.0	98.3	99.1	100.0	97.6	97.7	98.4	97.7	97.8	99.4	96.1	95.9	96.2	100.0	96.9	96.8	98.0
10-14	97.8	97.8	98.6	98.1	97.3	97.6	99.0	98.6	95.9	95.5	96.8	97.9	95.9	95.9	99.6	97.1	97.1	97.9	97.4	98.0	97.5	98.1
15-19	96.2	95.9	96.3	95.5	96.7	96.3	95.9	96.1	97.6	98.6	97.6	96.9	96.6	96.6	96.2	97.0	97.0	98.3	96.7	97.7	97.9	98.1
20-29	91.9	93.4	93.5	93.8	92.6	94.6	92.7	93.6	93.5	93.7	93.4	94.4	94.4	93.2	93.2	92.9	94.4	95.4	95.1	95.5	93.9	94.9
30-39	89.4	89.2	89.2	90.2	88.9	89.5	89.9	89.6	90.2	91.1	90.5	90.8	90.4	90.6	90.6	88.9	90.3	91.1	91.2	91.0	91.2	91.4
40-49	88.2	87.3	86.9	87.8	88.0	87.9	87.8	88.4	89.2	89.0	89.7	88.7	89.0	89.7	89.1	89.2	89.6	90.2	89.1	89.7	89.6	89.3
50-59	83.4	83.5	84.2	81.7	82.2	82.3	83.0	83.5	84.0	83.7	84.9	84.8	85.7	86.4	85.7	86.4	85.7	85.8	85.6	86.1	85.6	86.0
60-64	78.3	77.8	78.3	77.7	76.2	76.6	77.5	76.7	77.1	78.2	79.0	79.9	79.9	81.8	81.2	80.2	81.7	81.9	80.2	81.3	80.9	81.7
65-69	72.9	73.6	73.7	72.1	72.8	71.2	73.2	73.2	73.5	73.9	75.6	75.2	75.6	77.5	76.6	77.1	77.9	76.9	76.4	76.6	77.2	77.0
70-79	66.9	68.1	68.3	65.4	66.3	66.7	66.3	65.6	66.2	67.4	68.4	68.3	68.5	70.0	70.2	70.3	70.9	69.8	69.9	69.6	69.5	69.8
80+	58.5	54.4	63.1	55.0	56.8	58.0	59.1	55.6	55.8	57.7	59.5	59.3	58.5	61.2	61.1	60.4	60.4	59.4	57.5	58.4	57.9	58.0
Male	81.3	82.1	81.7	79.2	79.3	78.9	78.9	78.6	78.5	79.0	79.8	79.3	79.3	80.6	80.1	79.7	80.1	79.8	79.2	79.4	79.0	79.4
Female	82.1	81.7	82.1	79.7	79.9	79.4	80.1	78.7	79.8	79.3	79.9	79.3	79.6	80.2	80.0	79.6	79.6	78.9	78.1	78.1	77.9	77.9
White	80.9	81.0	80.6	77.8	77.6	77.4	77.6	76.5	76.8	76.9	77.5	76.8	76.8	78.0	77.7	77.7	76.8	76.4	76.6	76.6	76.3	76.2
Black	83.0	84.0	84.5	82.4	83.9	82.6	83.2	83.3	83.6	83.2	84.2	83.8	84.1	84.5	83.9	83.0	83.6	83.9	82.7	82.5	82.0	82.6
Other race	82.0	80.5	85.6	82.3	80.6	82.2	81.7	78.2	81.4	85.0	85.8	86.5	85.1	86.7	85.6	83.4	83.6	83.9	82.2	83.2	84.2	85.7
†Hispanic																						
†Non-Hispanic																						
Diabetes	75.8	74.2	73.8	73.9	74.5	73.9	75.6	75.3	76.6	77.2	77.2	77.6	77.7	79.5	79.4	78.7	79.0	78.4	77.5	78.2	78.1	78.3
Hypertension	83.8	82.0	80.3	78.5	78.0	78.8	78.0	76.5	77.1	77.0	78.1	77.3	77.4	78.0	77.9	78.5	78.6	77.6	76.9	76.8	76.6	76.7
Glomerulonephritis	91.7	89.5	89.0	87.6	87.9	87.9	86.6	87.0	87.3	87.4	87.5	86.6	88.2	89.1	87.7	88.3	88.7	88.5	88.7	88.2	88.4	88.8
Other cause	79.9	82.5	84.8	79.8	80.7	79.5	80.8	79.8	79.7	79.8	81.7	80.6	80.5	80.6	80.2	78.4	78.6	79.2	78.4	78.2	77.2	77.6
All	81.6	81.9	81.9	79.4	79.6	79.1	79.4	78.6	79.1	79.1	79.9	79.3	79.4	80.4	80.1	79.7	79.9	79.4	78.7	78.8	78.5	78.7
ADJUSTED																						
0-19	92.8	92.9	92.6	92.1	91.7	92.1	93.8	93.3	91.7	92.8	92.8	92.2	92.8	92.1	94.7	92.3	93.1	94.3	93.2	93.3	92.1	94.1
20-44	88.2	88.6	88.8	89.4	89.1	89.1	89.7	89.3	90.3	89.9	90.6	90.0	90.3	90.1	90.2	89.2	89.2	90.6	91.2	90.7	90.9	90.8
45-64	79.8	80.1	81.0	79.8	79.9	80.2	81.2	81.3	81.9	82.7	83.7	83.9	84.5	85.5	85.5	85.5	86.1	85.2	85.9	85.6	85.9	85.9
65-74	69.4	70.3	71.9	68.9	69.9	68.9	70.3	70.4	71.1	71.8	73.4	73.0	73.6	75.6	74.7	75.5	76.3	75.4	75.3	75.5	75.6	75.6
75+	60.4	62.0	61.9	58.6	60.8	62.1	62.1	59.5	60.1	62.3	63.3	63.5	62.9	64.3	65.2	64.6	65.0	64.0	63.3	63.4	63.3	63.5
Male	73.3	74.3	74.6	73.0	73.5	73.6	74.2	74.2	74.5	75.7	77.1	77.0	77.3	78.9	78.7	78.5	79.5	79.6	79.1	79.7	79.4	79.8
Female	74.9	74.9	76.5	75.1	75.7	75.7	77.1	76.3	77.5	77.8	78.9	78.7	79.2	79.9	80.1	80.0	80.4	80.1	79.4	79.5	79.5	79.6
White	72.0	72.4	73.2	71.6	71.8	72.3	73.3	72.9	73.8	74.8	75.9	75.8	76.3	77.7	78.0	78.2	78.8	78.4	78.2	78.7	78.6	78.6
Black	78.4	78.8	79.6	78.5	79.9	78.8	79.8	80.1	80.2	80.0	81.5	81.4	81.8	82.1	81.6	80.8	81.7	82.3	81.0	80.9	80.5	81.2
Other race	74.0	73.6	78.3	76.8	74.9	77.9	78.6	74.7	78.6	82.8	83.8	83.5	83.5	85.5	84.4	82.9	83.6	84.0	82.2	83.6	84.3	85.6
Diabetes	69.1	67.6	67.9	68.5	69.6	69.3	71.8	72.0	73.7	74.8	75.4	76.1	76.5	78.5	78.6	78.1	78.8	78.5	77.8	78.6	78.6	79.0
Hypertension	80.6	79.6	78.6	77.9	77.5	79.1	79.0	78.0	78.5	79.0	80.2	79.8	79.8	80.7	80.6	81.2	81.6	80.9	80.7	80.6	80.6	80.5
Glomerulonephritis	85.2	82.7	82.4	81.4	82.3	83.0	81.5	82.1	82.2	83.1	83.2	82.5	84.4	85.4	84.4	84.9	85.9	85.7	85.4	85.4	85.6	85.5
Other cause	75.7	77.1	80.0	76.8	77.2	75.8	77.3	76.6	76.4	76.7	78.7	77.9	77.9	77.7	77.7	76.0	76.2	77.3	76.2	76.3	75.4	75.8
All	74.1	74.6	75.5	74.0	74.5	74.6	75.6	75.2	76.0	76.7	77.9	77.8	78.3	79.4	79.4	79.2	80.0	79.8	79.3	79.6	79.5	79.7

Reference cohort is 1996 incident ESRD patients. Overall adjusted survival probabilities are adjusted for age, gender, race, & primary diagnosis. Adjusted survival probabilities for one of the four variables are adjusted for the remaining three. The incident cohorts are determined at the time of ESRD initiation with the 60-day stable modality rule & the 90-day rule. The age of the incident patient is determined as of the date of ESRD initiation. Patients of unknown age, gender, & age > 110 are excluded. Includes U.S. & territories; no unknown or foreign states. †CMS began collecting Hispanic ethnicity data in April 1995; cells for years prior to 1996 have therefore been left blank.

Table I.3
Two-year Survival Probabilities: Incident ESRD Patients
from day 91 to two years + 90 days, by age, gender, race, ethnicity, & primary diagnosis

UNADJUSTED	1980	1981	1982	1983	1984	1985	1986	1987	1988	1989	1990	1991	1992	1993	1994	1995	1996	1997	1998	1999	2000
0-4	87.5	90.6	85.4	83.5	84.6	85.0	87.5	85.8	77.8	81.1	80.3	84.2	89.3	84.5	87.3	84.6	87.6	86.0	84.9	84.7	79.4
5-9	91.5	93.4	93.3	94.5	93.5	94.0	94.2	97.3	97.0	96.9	94.6	97.6	97.7	94.1	96.9	95.4	95.3	95.5	97.8	95.1	96.2
10-14	95.5	95.1	96.8	97.2	95.5	95.8	96.1	98.6	95.0	94.0	94.9	97.1	94.2	93.9	98.5	95.3	96.0	96.1	95.6	97.4	96.4
15-19	94.8	92.9	93.4	93.0	93.8	94.4	93.5	94.6	95.0	96.9	95.6	94.3	95.1	94.2	94.8	95.3	93.6	95.3	94.7	95.2	94.7
20-29	86.5	87.8	88.7	87.6	88.4	87.0	89.3	86.6	89.2	89.5	88.9	88.6	89.7	90.3	89.2	88.4	90.3	91.0	91.4	91.4	89.2
30-39	80.7	81.7	80.8	82.7	80.5	80.8	81.5	81.7	83.7	83.0	83.6	82.8	83.4	83.8	82.6	82.3	83.2	84.5	84.4	84.8	85.1
40-49	77.4	76.9	76.8	76.6	77.8	78.2	77.5	78.5	79.6	79.1	80.9	78.5	80.0	80.4	80.3	81.5	80.7	80.4	80.7	80.9	81.0
50-59	70.7	70.7	71.0	68.5	68.0	68.2	68.9	69.1	70.0	71.1	71.6	71.9	73.0	73.9	74.4	73.2	73.6	74.0	73.2	74.3	74.1
60-64	63.7	61.6	62.0	62.1	59.5	59.2	61.3	60.1	61.1	62.1	62.9	63.7	64.0	66.6	66.1	65.0	66.9	67.1	65.5	67.2	67.4
65-69	54.9	56.1	55.3	52.5	55.3	53.1	54.1	55.6	56.1	56.2	56.8	57.1	58.3	60.5	59.2	59.9	61.1	59.6	59.6	60.0	61.5
70-79	46.6	48.8	49.1	44.4	46.6	47.0	46.6	45.8	46.7	47.9	48.0	48.3	49.2	50.3	50.5	50.8	51.8	50.0	51.1	51.1	50.8
80+	31.5	34.9	38.6	30.0	36.6	36.0	35.6	33.4	33.5	37.4	37.0	36.2	36.8	37.9	38.7	38.5	38.7	37.1	37.1	37.4	37.3
Male	68.0	69.3	68.7	65.0	65.5	64.1	64.6	63.9	64.6	65.0	65.2	64.6	65.0	66.6	66.0	65.9	66.0	65.4	65.3	65.6	65.6
Female	69.7	69.2	68.9	65.4	66.0	65.8	65.3	64.6	65.6	65.4	65.3	64.5	65.3	65.8	65.3	64.8	65.2	64.0	63.6	63.8	63.4
White	67.7	68.3	67.1	63.2	63.3	62.8	62.6	61.8	61.8	62.0	61.8	61.1	61.5	62.4	62.1	62.0	62.1	60.9	61.2	61.5	61.2
Black	70.4	71.6	72.3	68.9	70.9	69.3	70.2	69.6	71.7	71.2	71.6	70.7	71.8	72.9	71.9	71.2	71.7	71.6	70.4	70.3	70.2
Other race	70.6	66.3	74.0	69.4	67.3	66.4	65.6	64.6	67.8	72.8	73.1	75.2	74.4	75.7	73.7	70.7	71.4	71.5	69.4	71.6	72.8
†Hispanic																		70.9	70.1	70.7	73.3
†Non-Hispanic																		64.9	64.1	63.7	63.3
Diabetes	58.5	56.6	55.1	56.8	55.5	55.9	57.2	57.3	59.0	60.1	59.3	59.8	60.6	62.7	62.5	61.8	62.3	61.5	61.0	62.1	62.3
Hypertension	72.0	68.6	66.8	63.7	64.7	63.6	63.0	61.4	63.0	62.5	62.5	61.8	62.7	63.0	63.3	63.9	64.1	62.5	62.1	62.1	62.0
Glomerulonephritis	83.1	80.4	79.7	77.8	78.8	77.5	76.4	76.8	78.2	77.5	78.0	76.6	78.5	80.0	78.3	79.1	79.5	79.1	80.4	79.5	79.9
Other cause	66.7	71.2	73.8	65.7	68.3	67.6	68.6	67.7	67.3	68.5	70.2	68.8	68.9	69.0	67.9	66.8	67.1	67.6	67.2	67.0	66.0
All	68.7	69.3	68.8	65.2	65.7	64.9	64.9	64.2	65.0	65.2	65.2	64.5	65.2	66.2	65.7	65.4	65.6	64.8	64.5	64.8	64.6
ADJUSTED																					
0-19	89.4	88.0	88.1	87.5	87.5	88.3	88.3	90.4	87.6	89.7	88.5	88.8	90.3	87.2	91.2	89.1	88.8	90.1	89.6	90.2	87.9
20-44	78.2	79.9	80.2	80.6	80.5	80.4	81.3	80.8	82.8	82.5	83.1	81.8	82.7	82.9	82.5	82.0	83.1	84.5	83.7	84.2	84.1
45-64	65.6	65.2	66.3	65.1	64.6	65.0	66.3	66.4	67.6	69.2	70.1	70.4	71.4	73.1	73.2	72.7	73.6	74.2	73.3	74.4	74.4
65-74	49.7	51.8	52.9	48.2	51.4	50.0	50.9	51.8	53.0	53.6	54.1	54.5	55.8	57.4	56.7	58.0	58.9	57.5	58.2	58.7	59.1
75+	37.8	41.5	40.0	35.7	39.8	40.8	40.2	38.2	38.7	42.0	41.7	41.7	42.1	43.3	44.0	43.4	44.7	42.9	43.5	43.7	43.6
Male	56.5	58.0	58.2	56.1	57.2	56.5	58.1	57.7	58.9	60.5	61.1	61.2	62.2	64.1	64.0	64.2	65.2	65.2	65.3	66.1	66.2
Female	59.3	59.5	60.7	58.8	60.0	60.6	60.9	61.2	62.3	63.3	63.8	63.7	64.8	65.5	65.5	65.5	66.5	65.9	65.6	66.0	66.0
White	55.0	56.3	56.5	54.4	55.4	55.8	56.5	56.7	57.5	59.2	59.7	59.8	60.9	62.1	62.5	63.0	64.0	63.5	64.0	64.7	64.7
Black	63.3	63.6	64.7	62.8	64.7	63.5	65.1	64.5	66.6	66.4	67.3	66.9	68.0	69.3	68.5	68.0	68.9	69.0	67.9	67.8	68.1
Other race	59.1	56.4	62.2	60.5	59.3	59.8	60.6	59.6	63.5	69.4	69.8	72.6	71.8	73.7	71.8	70.0	71.4	71.8	69.4	72.3	73.0
Diabetes	49.8	48.3	47.8	50.0	49.3	50.2	52.1	53.1	55.2	57.0	57.0	57.9	59.1	61.5	61.6	61.3	62.3	61.9	61.7	63.0	63.4
Hypertension	66.9	65.0	64.5	62.9	64.2	64.3	64.5	63.6	65.1	65.5	65.8	65.7	66.4	67.1	67.5	68.1	68.8	67.5	67.8	67.8	67.8
Glomerulonephritis	71.2	69.1	68.8	67.8	69.7	69.2	68.3	68.8	70.1	70.5	71.0	69.9	72.1	73.7	72.8	73.3	74.5	74.1	74.9	74.7	75.2
Other cause	60.8	63.5	66.4	61.2	63.1	62.2	63.5	63.0	62.4	64.1	65.7	64.7	65.2	65.2	64.4	63.4	63.8	64.8	64.1	64.3	63.5

Reference cohort is 1996 incident ESRD patients. Overall adjusted survival probabilities are adjusted for age, gender, race, & primary diagnosis. Adjusted survival probabilities for one of the four variables are adjusted for the remaining three. The incident cohorts are determined at the time of ESRD initiation with the 60-day stable modality rule & the 90-day rule. The age of the incident patient is determined as of the date of ESRD initiation. Patients of unknown age, gender, & age >110 are excluded. Includes U.S. & territories; no unknown or foreign states. †CMS began collecting Hispanic ethnicity data in April 1995; cells for years prior to 1996 have therefore been left blank.

Table I.4

Five-year Survival Probabilities: Incident ESRD Patients

from day 91 to five years + 90 days, by age, gender, race, ethnicity, & primary diagnosis

UNADJUSTED	1980	1981	1982	1983	1984	1985	1986	1987	1988	1989	1990	1991	1992	1993	1994	1995	1996	1997
0-4	81.2	78.1	80.2	78.0	77.9	81.1	78.1	77.6	74.8	77.6	75.6	80.7	84.6	79.0	84.5	79.9	82.0	80.1
5-9	87.2	90.1	86.5	90.1	89.7	90.0	90.9	95.5	94.0	93.7	90.8	95.2	93.8	91.1	94.4	92.8	90.5	94.7
10-14	88.8	85.9	91.8	91.9	91.0	90.6	92.2	95.8	91.0	89.0	90.3	92.5	88.8	89.4	93.1	93.1	93.1	92.4
15-19	89.9	87.3	88.1	89.3	87.1	85.7	88.3	87.7	88.0	89.7	90.2	88.7	91.0	88.7	90.6	90.2	88.3	89.7
20-29	78.0	76.7	78.5	76.4	76.9	76.5	79.5	77.3	80.1	79.2	79.5	79.8	79.9	80.9	80.4	79.2	81.5	82.0
30-39	65.2	66.4	64.9	65.8	65.4	65.1	67.0	64.7	68.9	69.2	69.1	68.0	68.0	69.3	68.0	68.0	68.7	70.2
40-49	55.8	55.7	55.9	54.0	57.4	56.7	57.6	58.7	59.8	58.2	59.7	58.1	59.5	59.8	59.2	60.2	59.2	60.8
50-59	42.1	43.1	42.0	40.7	40.6	39.9	42.0	43.2	42.6	42.9	43.4	44.9	44.1	45.9	45.8	45.6	45.5	47.0
60-64	31.8	31.9	30.4	30.3	28.3	28.3	30.0	29.4	31.3	31.0	32.1	31.9	32.6	34.1	34.2	33.4	34.7	36.3
65-69	23.4	25.0	24.3	21.0	22.7	22.9	22.4	23.6	23.7	23.8	23.9	23.1	24.8	25.5	26.2	26.0	26.8	26.2
70-79	16.0	16.2	17.2	14.1	15.5	15.9	15.2	16.0	15.9	16.4	15.9	16.3	16.2	17.1	16.8	17.6	18.4	17.5
80+	8.9	7.9	7.9	6.5	8.1	8.3	7.9	8.2	7.1	9.2	8.9	7.9	7.8	8.4	8.5	9.1	9.3	8.4
Male	44.7	44.8	44.4	40.1	40.7	39.4	40.2	39.7	40.2	40.2	39.8	39.0	38.6	40.1	39.3	39.9	39.3	38.8
Female	44.8	45.8	44.0	40.2	40.8	40.1	39.9	39.1	39.9	38.4	38.1	37.2	37.5	37.6	37.2	36.6	36.4	36.4
White	44.9	44.6	43.1	38.7	39.3	38.5	38.5	37.3	37.0	36.4	35.6	34.7	34.4	35.1	34.5	34.4	34.1	33.5
Black	44.3	46.9	46.0	42.4	44.1	42.2	43.7	43.5	46.1	44.7	45.2	44.3	44.6	45.4	44.6	45.2	44.6	45.0
Other race	44.9	42.3	50.9	46.5	40.8	41.4	40.8	44.2	45.0	48.6	47.9	48.9	48.3	49.5	47.8	43.5	44.4	45.8
†Hispanic																	43.8	43.8
†Non-Hispanic																	37.2	36.9
Diabetes	31.4	28.8	26.9	27.6	27.2	27.4	29.3	28.6	29.9	29.4	28.8	28.8	29.5	30.5	30.7	29.9	30.0	30.0
Hypertension	47.6	42.7	40.6	38.0	38.0	36.7	36.2	35.0	36.6	35.2	35.9	34.3	34.7	34.7	34.7	36.0	35.9	35.4
Glomerulonephritis	66.0	62.0	59.9	57.6	57.7	55.7	56.1	56.7	58.3	57.9	58.0	57.2	58.1	59.8	58.2	59.3	59.0	59.3
Other cause	41.8	47.7	50.4	41.7	45.5	45.3	46.1	46.1	45.8	47.6	47.4	47.1	46.0	47.2	46.1	46.2	46.2	47.0
All	44.7	45.3	44.2	40.1	40.8	39.7	40.1	39.4	40.0	39.4	39.0	38.2	38.1	38.9	38.3	38.3	38.0	37.7
ADJUSTED																		
0-19	81.2	77.8	80.0	81.1	78.9	78.5	80.5	82.0	80.0	81.4	81.4	82.0	83.7	80.1	85.1	83.3	82.0	83.5
20-44	61.8	62.7	63.1	62.5	64.3	63.8	66.1	64.5	67.0	67.4	67.9	66.6	66.9	67.7	67.3	66.8	67.7	68.9
45-64	35.5	36.5	36.6	35.8	35.9	35.9	38.3	39.0	40.3	40.7	41.4	42.6	43.0	44.7	45.0	45.3	45.9	47.6
65-74	18.6	20.0	20.6	17.2	19.2	19.5	19.0	20.6	21.0	21.4	21.6	21.1	22.5	23.1	23.6	24.1	25.1	24.4
75+	10.8	11.1	11.1	8.8	10.5	11.0	11.0	10.9	10.3	12.1	11.0	11.7	10.7	11.8	11.6	12.4	13.1	12.4
Male	31.1	31.2	31.7	29.7	31.0	30.9	32.4	32.6	33.4	34.8	34.7	34.9	35.1	36.8	36.8	37.5	38.4	38.4
Female	32.4	34.1	34.0	32.6	33.9	34.0	34.8	35.2	35.9	35.9	36.3	36.4	37.1	37.5	37.8	38.0	38.6	39.0
White	30.2	30.3	30.8	28.9	30.3	30.6	31.5	31.7	32.1	33.3	33.0	33.3	33.9	35.0	35.4	35.8	36.9	36.8
Black	34.8	36.5	35.7	34.3	35.8	34.9	36.9	37.1	38.9	38.1	39.3	39.2	39.4	40.4	40.0	40.9	40.8	41.5
Other race	30.9	31.4	34.7	35.2	31.2	33.7	34.4	38.1	39.0	43.6	42.3	44.7	44.3	46.2	45.0	42.9	44.6	46.4
Diabetes	23.9	22.0	21.5	22.3	22.6	23.2	25.3	25.5	26.8	27.1	27.2	28.0	28.9	30.2	30.7	30.5	31.3	31.5
Hypertension	41.0	38.4	38.0	37.4	37.7	37.7	38.2	38.2	39.2	39.0	40.0	39.3	39.4	40.0	40.1	41.3	41.9	41.6
Glomerulonephritis	46.7	44.8	43.5	43.0	43.9	42.9	43.9	44.6	45.7	46.7	46.4	47.0	47.5	49.0	48.9	49.6	50.3	50.4
Other cause	34.7	37.9	40.1	35.3	38.3	38.2	39.1	39.5	39.2	41.5	40.7	41.2	40.6	41.8	41.1	41.2	41.5	42.7
All	31.7	32.5	32.8	31.1	32.3	32.4	33.5	33.8	34.6	35.3	35.5	35.7	36.1	37.2	37.3	37.8	38.5	38.7

Reference cohort is 1996 incident ESRD patients.

Overall adjusted survival probabilities are adjusted for age, gender, race, & primary diagnosis.

Adjusted survival probabilities for one of the four variables are adjusted for the remaining three.

The incident cohorts are determined at the time of ESRD initiation with the 60-day stable modality rule & the 90-day rule.

The age of the incident patient is determined as of the date of ESRD initiation.

Patients of unknown age, gender, & age > 110 are excluded. Includes U.S. & territories; no unknown or foreign states.

†CMS began collecting Hispanic ethnicity data in April 1995; cells for years prior to 1996 have therefore been left blank.



Table I.5
Ten-year Survival Probabilities: Incident ESRD Patients

from day 91 to ten years + 90 days, by age, gender, race, & primary diagnosis

UNADJUSTED	1980	1981	1982	1983	1984	1985	1986	1987	1988	1989	1990	1991	1992
0-4	79.2	70.3	76.0	73.4	73.1	74.0	76.6	76.1	66.7	74.8	70.9	76.6	77.7
5-9	79.8	81.3	78.8	82.4	86.9	83.0	86.8	83.8	91.0	87.4	85.4	90.4	89.9
10-14	79.8	78.4	78.6	83.4	82.1	83.0	85.8	90.2	82.8	81.0	81.1	86.7	83.0
15-19	80.0	78.9	80.0	81.0	78.8	77.3	79.1	78.4	79.5	83.5	83.2	80.3	80.7
20-29	64.5	62.4	65.1	64.0	64.7	65.3	66.4	65.5	68.4	66.1	67.5	66.0	67.2
30-39	47.6	48.1	48.5	49.6	49.4	48.2	50.3	48.8	51.0	51.1	52.1	50.9	51.7
40-49	33.6	33.0	34.0	34.2	36.5	36.2	36.9	36.8	37.7	35.6	37.1	35.8	37.8
50-59	16.4	18.0	18.4	16.9	17.8	18.4	19.4	20.3	18.7	19.1	19.1	20.3	19.8
60-64	8.6	8.8	7.4	9.1	8.9	9.5	9.2	9.2	9.8	9.3	9.3	10.0	10.5
65-69	4.8	5.6	4.5	5.0	5.6	6.4	5.4	5.0	5.2	5.1	5.5	5.1	5.3
70-79	2.7	2.4	3.0	2.4	3.0	3.0	2.5	2.9	2.6	2.4	2.1	2.1	2.3
80+	3.1	2.3	3.3	0.6	2.1	1.2	1.2	1.3	0.6	0.9	0.5	0.8	0.6
Male	25.6	25.7	26.2	23.7	24.3	23.6	24.0	23.1	22.8	22.2	22.4	21.2	21.4
Female	25.5	25.8	24.7	22.4	23.2	22.6	21.8	20.9	21.4	19.9	19.0	18.8	18.7
White	27.3	26.8	26.1	23.7	24.2	23.4	23.1	22.1	21.3	20.2	19.9	19.0	18.9
Black	22.1	23.5	23.2	21.2	22.5	22.1	22.2	21.5	23.3	22.4	21.6	21.2	21.7
Other race	25.6	25.7	33.4	29.6	27.7	26.5	27.0	25.4	27.5	28.3	30.1	29.0	28.3
Diabetes	13.5	12.1	11.9	11.9	12.3	12.5	12.9	12.1	12.0	11.6	10.9	10.5	11.0
Hypertension	25.5	21.8	19.9	19.0	18.9	17.5	17.4	15.9	17.4	16.1	16.1	15.5	16.2
Glomerulonephritis	47.5	42.2	40.2	39.1	39.7	39.1	39.3	38.8	40.1	39.4	39.8	38.5	40.6
Other cause	23.0	27.7	31.1	25.8	29.0	29.4	29.6	29.8	29.3	29.9	30.8	30.6	29.3
All	25.6	25.8	25.5	23.1	23.8	23.2	23.0	22.1	22.1	21.2	20.8	20.1	20.1
ADJUSTED													
0-19	69.2	67.2	67.8	70.4	69.1	68.1	71.4	71.7	69.8	73.4	72.2	73.0	72.8
20-44	43.6	43.2	45.2	45.6	47.2	47.2	48.6	47.3	49.0	49.0	49.8	48.4	49.5
45-64	12.9	14.0	14.5	14.4	15.4	16.0	17.0	17.5	17.5	17.7	17.9	18.8	19.7
65-74	3.3	3.6	3.5	3.5	4.2	4.8	4.1	4.2	4.1	4.1	4.4	4.0	4.4
75+	2.0	2.0	2.4	1.1	1.9	1.6	1.4	1.8	1.5	1.4	0.9	1.2	1.2
Male	14.8	14.8	15.7	15.2	16.2	16.7	17.2	17.1	16.9	17.3	17.7	17.5	18.1
Female	15.9	16.7	16.7	16.4	17.6	17.7	17.6	17.8	18.1	17.7	17.7	18.1	18.4
White	15.4	15.3	15.9	15.6	16.6	16.9	17.0	17.3	17.0	17.2	17.4	17.5	18.1
Black	14.5	15.3	15.2	14.9	15.9	16.3	16.5	16.4	17.3	16.7	16.7	17.0	17.3
Other race	14.4	16.7	18.7	19.3	18.9	19.2	20.3	19.8	21.4	22.8	23.8	24.2	24.0
Diabetes	9.5	9.1	9.4	9.5	10.0	10.5	10.9	11.0	10.9	10.8	10.8	10.8	11.5
Hypertension	20.5	19.0	18.5	19.0	19.1	18.8	19.1	18.8	19.3	19.0	19.1	19.0	19.6
Glomerulonephritis	26.2	24.1	23.4	23.8	25.2	25.7	26.0	25.9	26.2	26.4	26.4	26.7	28.3
Other cause	17.2	19.1	21.0	19.3	21.7	22.2	22.1	22.7	22.2	23.0	23.4	23.9	23.2
All	15.3	15.7	16.2	15.8	16.8	17.2	17.4	17.4	17.5	17.5	17.7	17.8	18.3

Reference cohort is 1996 incident ESRD patients.

Overall adjusted survival probabilities are adjusted for age, gender, race, & primary diagnosis.

Adjusted survival probabilities for one of the four variables are adjusted for the remaining three.

The incident cohorts are determined at the time of ESRD initiation with the 60-day stable modality rule & the 90-day rule.

The age of the incident patient is determined as of the date of ESRD initiation.

Patients of unknown age, gender, & age >110 are excluded. Includes U.S. & territories; no unknown or foreign states.

Table I.6

Incident Patient Counts: ESRD Patients Age 65 & Over*patients age 65 & over on day 1, by age, gender, race, ethnicity, & primary diagnosis*

	1980-81	1982-83	1984-85	1986-87	1988-89	1990-91	1992-93	1994-95	1996-97	1998-99	2000-01
65-69	4,376	5,900	7,392	9,512	12,072	15,187	17,550	19,260	21,372	22,446	23,093
70-74	3,274	4,990	6,374	8,150	10,215	13,456	16,701	19,188	22,213	23,794	24,749
75-79	1,885	3,032	4,262	5,810	7,750	9,955	12,312	14,545	17,975	21,371	22,974
80-84	682	1,224	1,828	2,652	3,730	5,124	6,677	8,276	10,750	12,959	14,895
85+	209	424	631	916	1,412	2,056	2,738	3,451	4,869	6,714	8,059
Male	5,727	8,344	10,861	14,136	18,281	23,634	28,598	32,528	39,684	44,963	48,275
Female	4,699	7,226	9,626	12,904	16,898	22,144	27,380	32,192	37,495	42,321	45,495
White	7,180	11,295	14,811	19,658	25,802	33,572	41,063	46,887	55,974	63,675	68,910
Black	2,868	3,864	5,012	6,429	8,231	10,686	12,887	14,743	17,180	18,925	19,950
Other race	378	411	664	953	1,146	1,520	2,028	3,090	4,025	4,684	4,910
†Hispanic									6,997	7,964	8,931
†Non-Hispanic									70,182	79,320	84,839
Diabetes	1,342	2,657	4,202	6,427	9,456	13,962	18,409	23,632	31,645	36,647	40,318
Hypertension	2,687	5,209	7,246	10,055	13,723	18,062	21,835	23,472	26,349	29,937	31,761
Glomerulonephritis	1,090	1,856	2,455	2,899	3,405	4,078	4,389	5,160	5,739	5,696	5,249
Cystic kidney	279	405	448	542	573	692	737	924	1,019	1,061	1,092
Other urologic	396	476	682	788	893	990	965	1,079	1,551	1,651	1,690
Other cause	1,118	2,003	2,516	3,101	3,590	3,967	4,659	5,947	7,198	8,115	9,000
Unknown cause	1,285	1,482	1,839	2,558	3,043	3,686	4,552	4,310	3,475	3,895	4,405
Missing cause	2,229	1,482	1,099	670	496	341	432	196	203	282	255
All	10,426	15,570	20,487	27,040	35,179	45,778	55,978	64,720	77,179	87,284	93,770

The incident cohorts are determined at the time of ESRD initiation with the 60-day stable modality rule.

The age of the incident patient is determined as of the date of ESRD initiation.

Patients of unknown age or gender, or of age >110 are excluded.

†CMS began collecting Hispanic ethnicity data in April 1995; cells for years prior to 1996 have therefore been left blank.

Includes patients from U.S. & territories only.



Table I.7

One-year Survival Probabilities: Incident ESRD Patients Age 65 & Over

from day 1 to one year, by age, gender, race, ethnicity, & primary diagnosis

UNADJUSTED	1980-81	1982-83	1984-85	1986-87	1988-89	1990-91	1992-93	1994-95	1996-97	1998-99	2000-01
65-69	71.1	71.0	70.0	72.2	73.1	74.0	75.3	75.7	75.5	75.1	74.9
70-74	66.5	67.2	65.0	66.2	67.0	68.3	70.0	70.3	70.1	69.9	69.2
75-79	61.1	60.4	62.0	60.9	61.3	63.9	63.5	64.6	64.2	63.3	63.4
80-84	53.8	56.9	55.5	56.3	57.5	57.8	59.1	59.0	58.7	56.7	56.0
85+	49.8	51.2	47.5	49.8	47.0	51.2	51.3	52.0	48.8	47.6	48.2
Male	65.3	64.0	63.0	63.9	64.4	66.1	67.2	67.3	66.6	65.7	65.2
Female	67.5	68.6	66.8	67.6	67.8	68.6	68.9	69.1	68.0	66.2	65.4
White	65.1	63.9	62.7	63.0	63.5	64.7	65.5	65.8	65.2	64.2	63.5
Black	69.1	72.4	70.9	73.5	73.2	74.2	74.9	74.6	72.9	70.6	69.6
Other race	67.7	66.7	66.3	68.1	71.5	76.4	76.2	73.9	72.5	71.1	73.1
†Hispanic									71.4	71.0	70.8
†Non-Hispanic									66.9	65.4	64.7
Diabetes	65.0	60.7	62.7	65.1	66.9	68.4	69.8	69.9	69.4	67.9	67.8
Hypertension	68.3	65.5	64.9	64.9	64.9	65.9	65.9	66.8	66.3	65.2	64.2
Glomerulonephritis	74.1	73.3	73.6	72.5	72.6	72.6	75.1	74.3	74.5	73.5	73.8
Other cause	64.0	66.8	62.7	64.5	64.2	66.1	66.4	65.1	61.1	59.8	58.7
All	66.3	66.1	64.8	65.6	66.0	67.3	68.0	68.2	67.3	65.9	65.3
ADJUSTED											
65-69	68.9	69.4	68.7	71.2	72.6	73.7	75.2	75.7	75.8	75.5	75.4
70-74	64.8	65.9	63.8	65.4	66.3	68.0	69.9	70.2	70.3	70.2	69.6
75-79	59.7	59.0	60.9	59.9	60.6	63.4	63.3	64.4	64.3	63.5	63.8
80-84	52.5	56.0	54.5	55.6	56.8	57.2	58.6	58.6	58.6	56.7	56.2
85+	48.9	50.3	46.5	49.0	46.1	50.6	50.8	51.4	48.4	47.4	48.1
Male	61.0	60.6	60.2	61.5	62.5	64.7	66.3	66.7	66.6	66.4	66.3
Female	62.6	64.8	63.5	64.9	65.8	67.0	67.7	68.3	67.9	66.7	66.4
White	60.5	60.1	59.4	60.3	61.4	63.1	64.4	65.2	65.3	65.0	64.7
Black	65.7	69.8	68.5	71.3	71.3	72.6	73.5	73.5	72.2	70.1	69.5
Other race	63.2	63.9	63.6	65.8	70.3	75.0	75.2	73.2	72.5	71.5	73.7
Diabetes	59.0	55.6	57.9	60.6	63.0	65.0	66.7	67.1	67.1	66.2	66.5
Hypertension	65.7	63.7	63.6	64.1	64.7	66.1	66.5	67.7	67.9	67.3	66.8
Glomerulonephritis	71.7	71.4	72.2	71.4	71.8	72.3	74.9	74.6	75.1	74.6	74.9
Other cause	61.7	65.3	61.7	63.8	63.7	65.7	66.4	65.4	62.3	61.5	60.7
All	61.8	62.6	61.8	63.2	64.1	65.8	67.0	67.5	67.3	66.5	66.4

Reference cohort is 1996 incident ESRD patients. Overall adjusted survival probabilities are adjusted for age, gender, race, & primary diagnosis.

Adjusted survival probabilities for one of the four variables are adjusted for the remaining three.

The incident cohorts are determined at the time of ESRD initiation with the 60-day stable modality rule.

The age of the incident patient is determined as of the date of ESRD initiation. Patients of unknown age, gender, & age > 110 are excluded.

Includes U.S. & territories; no unknown or foreign states.

†CMS began collecting Hispanic ethnicity data in April 1995; cells for years prior to 1996 have therefore been left blank.

Table I.8

Two-year Survival Probabilities: Incident ESRD Patients Age 65 & Over

from day 1 to two years, by age, gender, race, ethnicity, & primary diagnosis

UNADJUSTED	1980-81	1982-83	1984-85	1986-87	1988-89	1990-91	1992-93	1994-95	1996-97	1998-99
65-69	53.4	52.4	51.9	53.7	55.5	56.3	58.5	58.8	59.2	58.8
70-74	47.4	47.9	46.7	47.3	48.2	49.3	51.1	51.9	51.9	52.6
75-79	41.7	39.6	41.2	40.8	41.9	43.7	44.6	45.3	45.2	44.9
80-84	33.4	34.8	35.8	33.8	35.8	36.9	38.1	39.1	38.4	37.0
85+	30.6	29.0	27.3	27.6	28.5	28.4	29.4	30.2	29.1	28.4
Male	46.2	43.8	43.4	44.1	45.4	46.9	48.1	48.7	48.2	48.0
Female	49.4	49.5	48.7	48.4	49.2	49.4	50.7	50.7	49.9	48.3
White	46.4	44.0	43.6	43.2	44.4	44.9	46.2	46.6	46.3	45.8
Black	50.9	53.5	52.5	55.0	55.4	56.5	57.9	57.8	56.4	54.1
Other race	45.8	46.2	46.5	47.1	52.4	59.8	60.0	56.9	56.1	54.8
†Hispanic									53.2	53.8
†Non-Hispanic									48.6	47.5
Diabetes	41.8	38.4	41.5	42.5	45.2	47.0	49.5	49.8	49.6	48.9
Hypertension	49.7	45.6	46.5	45.5	47.0	47.0	47.6	48.9	48.6	47.4
Glomerulonephritis	54.6	55.0	54.7	53.7	54.9	55.4	57.6	57.1	57.1	57.0
Other cause	46.7	48.1	44.7	47.3	46.7	48.6	49.4	47.8	45.2	44.2
All	47.6	46.5	45.9	46.1	47.2	48.1	49.4	49.7	49.0	48.1
ADJUSTED										
65-69	50.1	49.9	49.9	52.2	54.6	55.8	58.3	58.9	59.7	59.4
70-74	45.0	45.9	44.9	46.0	47.3	48.8	50.8	51.8	52.2	53.0
75-79	39.7	37.8	39.7	39.4	40.9	43.1	44.2	44.9	45.2	45.2
80-84	31.7	33.5	34.5	32.7	35.0	36.1	37.5	38.6	38.2	37.0
85+	29.8	27.9	26.1	26.7	27.5	27.7	28.8	29.6	28.7	28.2
Male	40.8	39.5	39.8	41.1	43.0	45.0	46.8	47.9	48.3	48.8
Female	43.1	44.5	44.6	44.9	46.5	47.3	49.1	49.6	49.8	48.9
White	40.6	39.1	39.5	39.8	41.7	42.9	44.8	45.8	46.4	46.7
Black	46.4	49.8	49.3	51.9	52.8	54.2	55.9	56.2	55.4	53.4
Other race	39.7	42.4	43.3	44.2	50.9	57.9	58.5	56.1	56.2	55.4
Diabetes	35.1	32.9	36.2	37.2	40.6	42.6	45.5	46.3	46.8	46.7
Hypertension	46.5	43.4	44.9	44.5	46.7	47.3	48.3	50.0	50.5	50.0
Glomerulonephritis	51.4	52.5	52.8	52.2	53.9	55.2	57.4	57.6	58.0	58.6
Other cause	44.0	46.3	43.6	46.4	46.1	48.1	49.4	48.2	46.5	46.2
All	41.9	41.9	42.1	42.9	44.7	46.1	48.0	48.7	49.0	48.8

Reference cohort is 1996 incident ESRD patients. Overall adjusted survival probabilities are adjusted for age, gender, race, & primary diagnosis. Adjusted survival probabilities for one of the four variables are adjusted for the remaining three.

The incident cohorts are determined at the time of ESRD initiation with the 60-day stable modality rule.

The age of the incident patient is determined as of the date of ESRD initiation.

Patients of unknown age or gender, or of age >110 are excluded. Includes residents of the 50 states, the District of Columbia, Puerto Rico, & the Territories.

†CMS began collecting Hispanic ethnicity data in April 1995; cells for years prior to 1996 have therefore been left blank.



Table I.9

Five-year Survival Probabilities: Incident ESRD Patients Age 65 & Over

from day 1 to five years, by age, gender, race, ethnicity, & primary diagnosis

UNADJUSTED	1980-81	1982-83	1984-85	1986-87	1988-89	1990-91	1992-93	1994-95	1996-97
65-69	23.5	21.7	22.2	22.6	23.5	23.4	24.9	25.9	26.2
70-74	16.9	16.9	17.0	16.9	17.7	17.9	18.9	19.3	19.8
75-79	13.1	11.5	12.1	12.8	12.9	13.0	12.9	13.7	14.5
80-84	6.9	7.2	8.5	8.0	8.7	9.2	8.9	9.3	9.6
85+	9.6	5.7	5.1	5.7	5.6	5.3	5.6	5.9	5.5
Male	16.6	14.5	14.8	15.3	16.4	16.4	16.5	17.2	17.5
Female	20.1	19.0	18.8	18.5	18.1	17.9	18.8	18.9	18.5
White	17.1	15.4	15.2	14.9	15.2	14.7	15.2	15.5	15.7
Black	20.9	20.0	21.1	22.4	22.8	23.6	24.1	24.8	23.6
Other race	17.5	18.0	16.6	17.9	21.2	24.3	25.8	23.8	25.1
†Hispanic									20.5
†Non-Hispanic									17.7
Diabetes	12.0	10.1	12.0	13.0	13.3	14.0	15.4	16.2	16.2
Hypertension	19.3	16.9	16.6	16.5	17.0	16.8	16.8	17.8	18.0
Glomerulonephritis	22.1	22.7	21.9	22.1	23.1	23.2	24.7	24.8	25.3
Other cause	18.3	17.4	18.0	18.3	19.6	19.6	20.2	19.2	19.1
All	18.2	16.6	16.7	16.8	17.2	17.1	17.6	18.0	18.0
ADJUSTED									
65-69	20.2	19.2	20.1	21.0	22.5	22.7	24.6	25.9	26.7
70-74	14.9	15.1	15.5	15.9	16.8	17.3	18.6	19.1	20.0
75-79	11.5	10.3	10.9	11.8	12.2	12.4	12.6	13.4	14.5
80-84	6.2	6.5	7.8	7.5	8.3	8.7	8.6	9.0	9.5
85+	9.0	5.2	4.6	5.4	5.1	5.1	5.4	5.7	5.4
Male	12.6	11.6	12.4	13.2	14.5	14.9	15.4	16.5	17.4
Female	15.0	15.0	15.5	15.6	15.9	16.1	17.4	17.9	18.4
White	12.7	11.7	12.2	12.4	13.2	13.2	14.1	14.9	15.8
Black	17.0	16.7	18.4	19.7	20.2	21.5	22.0	23.1	22.6
Other race	13.0	15.1	14.4	15.5	19.9	22.4	24.2	22.9	25.0
Diabetes	8.4	7.5	9.2	10.0	10.6	11.3	12.7	13.7	14.2
Hypertension	16.7	15.1	15.4	15.8	16.7	16.9	17.3	18.6	19.6
Glomerulonephritis	19.7	20.9	20.5	21.1	22.4	23.2	24.7	25.2	26.1
Other cause	16.4	16.0	17.2	17.7	19.2	19.2	20.1	19.5	20.1
All	13.8	13.2	13.9	14.3	15.2	15.5	16.4	17.2	17.9

Reference cohort is 1996 incident ESRD patients. Overall adjusted survival probabilities are adjusted for age, gender, race, & primary diagnosis. Adjusted survival probabilities for one of the four variables are adjusted for the remaining three.

The incident cohorts and associated modalities are determined at the time of ESRD initiation with the 60-day stable modality rule.

The age of the incident patient is determined as of the date of ESRD initiation.

Patients of unknown age, gender, & age >110 are excluded. Includes U.S. & territories; no unknown or foreign states.

†CMS began collecting Hispanic ethnicity data in April 1995; cells for years prior to 1996 have therefore been left blank.

Table I.10
Ten-year Survival Probabilities: Incident ESRD Patients Age 65 & Over

from day 1 to ten years, by age, gender, & race, ethnicity, & primary diagnosis

UNADJUSTED	1980-81	1982-83	1984-85	1986-87	1988-89	1990-91	1992-93
65-69	5.2	4.7	6.0	5.2	5.1	5.3	5.6
70-74	2.8	3.0	3.3	3.2	2.8	2.6	3.0
75-79	1.9	1.6	1.8	1.9	1.7	1.3	1.7
80-84	1.2	1.2	1.3	1.0	0.8	0.7	0.8
85+	5.7	2.1	1.7	1.3	0.6	0.4	0.6
Male	3.2	2.6	3.4	3.2	2.8	2.7	2.9
Female	4.1	3.9	4.1	3.4	3.4	3.1	3.3
White	3.5	2.9	3.5	3.0	2.6	2.4	2.6
Black	3.9	4.0	4.5	4.0	4.3	4.2	4.3
Other race	3.2	5.8	3.5	5.1	4.5	6.1	6.4
Diabetes	2.0	2.0	2.3	2.0	1.7	1.7	2.0
Hypertension	3.6	3.0	3.2	2.8	2.6	2.4	2.7
Glomerulonephritis	4.3	4.3	5.3	5.3	5.1	5.1	5.3
Other cause	3.8	3.6	4.8	4.4	4.5	4.6	4.9
All	3.6	3.2	3.8	3.3	3.1	2.9	3.1
ADJUSTED							
65-69	4.0	3.7	5.1	4.5	4.6	5.0	5.4
70-74	2.3	2.4	2.8	2.9	2.6	2.5	2.9
75-79	1.5	1.4	1.6	1.7	1.5	1.2	1.6
80-84	1.0	1.1	1.1	0.9	0.8	0.7	0.7
85+	5.2	2.0	1.5	1.2	0.5	0.4	0.5
Male	2.1	1.8	2.6	2.6	2.2	2.3	2.6
Female	2.5	2.6	3.0	2.6	2.7	2.5	2.9
White	2.0	1.8	2.4	2.2	2.0	1.9	2.2
Black	2.7	2.8	3.5	3.2	3.4	3.4	3.6
Other race	2.0	4.7	2.8	4.0	3.9	5.0	5.6
Diabetes	1.3	1.5	1.7	1.4	1.2	1.2	1.5
Hypertension	3.0	2.5	2.8	2.7	2.6	2.5	2.9
Glomerulonephritis	3.7	3.9	4.8	5.0	4.8	5.2	5.2
Other cause	3.3	3.3	4.6	4.3	4.4	4.4	4.8
All	2.3	2.2	2.8	2.6	2.4	2.4	2.7

Reference cohort is 1996 incident ESRD patients. Overall adjusted survival probabilities are adjusted for age, gender, race, & primary diagnosis. Adjusted survival probabilities for one of the four variables are adjusted for the remaining three. The incident cohorts and associated modalities are determined at the time of ESRD initiation with the 60-day stable modality rule. The age of the incident patient is determined as of the date of ESRD initiation. Patients of unknown age or gender, or of age >110 are excluded. Includes residents of the 50 states, the District of Columbia, Puerto Rico, & the Territories.



Table I.11

Incident Patient Counts: Dialysis Patients

dialysis patients alive on day 91, by age, gender, race, ethnicity, & primary diagnosis

	1980	1981	1982	1983	1984	1985	1986	1987	1988	1989	1990	1991	1992	1993	1994	1995	1996	1997	1998	1999	2000	2001
0-4	33	49	68	87	84	101	108	99	99	110	96	137	116	130	114	135	130	133	139	129	158	162
5-9	67	64	75	71	77	60	85	82	68	78	88	70	73	76	117	99	98	89	96	112	108	102
10-14	146	152	182	168	160	154	136	140	146	127	156	167	176	178	193	193	206	210	199	225	225	234
15-19	366	396	373	380	346	350	340	353	410	425	397	391	460	431	402	454	478	438	461	487	479	470
20-29	1,310	1,455	1,657	1,598	1,730	1,773	1,834	1,843	1,980	2,137	2,204	2,282	2,445	2,460	2,491	2,400	2,478	2,397	2,487	2,386	2,452	2,435
30-39	1,968	2,198	2,448	2,544	2,725	2,896	3,114	3,223	3,637	4,008	4,166	4,424	4,788	4,884	5,257	5,204	5,299	5,259	5,234	5,446	5,256	5,218
40-49	2,222	2,533	2,648	2,967	3,079	3,355	3,559	3,983	4,416	5,082	5,510	6,243	6,789	7,251	7,741	8,335	8,939	8,942	9,676	9,840	10,084	10,049
50-59	3,485	4,119	4,401	4,518	4,778	5,088	5,350	5,730	6,503	7,069	7,548	8,238	9,204	9,688	11,018	11,292	11,910	12,941	14,036	15,100	15,532	16,271
60-64	1,968	2,269	2,593	2,996	3,301	3,624	3,762	4,268	4,641	5,083	5,538	6,127	6,467	6,766	7,224	7,541	7,926	8,331	8,779	9,020	9,285	9,555
65-69	1,957	2,009	2,300	3,051	3,118	3,516	4,045	4,620	5,157	5,940	6,607	7,343	7,937	8,243	8,864	8,891	9,677	9,951	10,227	10,344	10,404	10,633
70-79	2,163	2,359	2,910	4,149	4,284	4,998	5,749	6,602	7,250	8,597	9,604	11,296	12,617	13,248	14,840	15,252	17,224	18,376	19,395	20,574	20,995	21,085
80+	357	389	542	842	907	1,127	1,377	1,612	1,943	2,413	2,788	3,258	3,840	4,149	4,708	5,113	6,105	6,918	7,604	8,579	9,250	9,643
Male	8,897	9,862	11,036	12,732	13,540	14,618	16,022	17,494	19,356	22,046	23,957	26,604	28,912	30,537	33,212	34,104	37,437	39,281	41,575	43,888	45,029	46,067
Female	7,145	8,130	9,161	10,639	11,049	12,424	13,437	15,061	16,894	19,023	20,745	23,372	26,000	26,967	29,757	30,805	33,033	34,704	36,758	38,354	39,199	39,790
White	10,113	11,598	13,584	15,264	16,184	17,785	19,465	21,320	23,491	26,590	29,097	32,468	35,418	36,753	40,032	40,295	44,061	46,775	49,148	52,354	53,946	54,660
Black	5,331	5,760	5,991	7,302	7,495	8,228	8,835	9,947	11,233	12,957	13,806	15,466	17,156	18,124	19,793	20,514	22,049	22,670	24,133	24,633	24,759	25,487
Other race	598	634	622	805	910	1,029	1,159	1,288	1,526	1,522	1,799	2,042	2,338	2,627	3,144	4,100	4,360	4,540	5,052	5,255	5,523	5,710
†Hispanic																	8,315	8,508	9,033	9,820	10,484	10,833
†Non-Hispanic																	62,155	65,477	69,300	72,422	73,744	75,024
Diabetes	2,426	3,526	4,662	5,457	6,562	7,574	8,665	9,858	11,296	13,748	15,674	17,989	20,211	21,406	24,194	27,214	30,832	33,032	35,009	37,055	38,585	39,606
Hypertension	2,784	3,981	5,081	5,648	6,273	7,175	7,807	8,962	10,326	11,976	13,196	14,593	16,289	16,858	18,344	17,083	18,606	19,974	20,710	22,032	22,345	23,034
Glomerulonephritis	2,291	2,940	3,489	3,760	4,002	4,185	4,229	4,600	4,931	5,210	5,566	5,921	6,139	6,339	6,848	7,187	7,646	7,378	7,873	7,685	7,398	7,272
Cystic kidney	699	844	971	972	984	1,032	1,082	1,114	1,137	1,134	1,224	1,325	1,364	1,446	1,471	1,657	1,646	1,718	1,808	1,899	1,863	1,858
Other urologic	381	479	486	560	566	701	683	672	731	761	783	892	972	839	824	1,085	1,340	1,286	1,321	1,481	1,427	1,416
Other cause	1,785	2,375	3,026	3,219	3,316	3,597	3,815	3,979	4,143	4,677	4,624	5,032	5,438	5,585	6,199	7,483	7,501	7,707	8,475	8,800	9,042	9,134
Unknown cause	1,593	1,864	1,742	1,899	2,039	2,123	2,510	2,837	3,012	3,123	3,319	3,854	4,261	4,643	4,929	3,055	2,763	2,756	2,992	3,083	3,358	3,421
Missing cause	4,083	1,983	740	1,856	847	655	668	533	674	440	316	370	238	388	160	145	136	134	145	207	210	116
All	16,042	17,992	20,197	23,371	24,589	27,042	29,459	32,555	36,250	41,069	44,702	49,976	54,912	57,504	62,969	64,909	70,470	73,985	78,333	82,242	84,228	85,857

The incident cohorts are determined at the time of ESRD initiation with the 60-day stable modality rule & the 90 day rule. The age of the incident patient is determined as of the date of ESRD initiation.

Patients of unknown age or gender, or of age > 110 are excluded.

Includes residents of the 50 states; the District of Columbia, Puerto Rico, & the Territories; no unknown or foreign states.

†CMS began collecting Hispanic ethnicity data in April 1995; cells for years prior to 1996 have therefore been left blank.



Table I.12

One-year Survival Probabilities: Incident Dialysis Patients

censored at transplant, from day 91 to one year + 90 days, by age, gender, race, ethnicity, & primary diagnosis

UNADJUSTED	1980	1981	1982	1983	1984	1985	1986	1987	1988	1989	1990	1991	1992	1993	1994	1995	1996	1997	1998	1999	2000	2001
0-4	96.3	92.3	89.3	90.1	86.2	86.5	93.3	93.5	80.1	84.3	81.8	84.8	89.9	86.4	90.1	85.3	87.3	86.0	85.3	80.5	79.4	85.5
5-9	92.7	96.4	95.9	98.2	90.4	89.9	100.0	100.0	100.0	100.0	94.9	95.7	93.9	96.8	100.0	96.8	92.1	97.4	100.0	97.0	95.6	96.8
10-14	96.4	98.6	97.7	98.4	96.8	97.6	98.9	99.0	96.1	96.1	95.4	97.8	94.1	94.4	99.3	96.7	96.1	96.4	96.6	96.8	96.4	97.7
15-19	90.7	94.6	93.3	95.3	96.8	93.8	97.4	95.3	97.4	98.4	97.1	96.5	96.9	96.3	97.8	95.7	97.3	97.4	97.4	97.3	97.4	97.2
20-29	90.7	92.7	92.2	92.4	92.7	91.1	93.5	91.1	92.5	92.3	92.5	92.5	93.4	92.9	92.2	91.7	93.5	94.8	94.2	94.6	92.9	94.2
30-39	88.8	89.2	88.4	89.6	87.3	88.1	88.5	88.1	89.2	88.9	89.9	89.1	89.7	89.1	89.4	87.5	89.2	90.1	90.1	90.0	90.2	90.3
40-49	88.0	87.3	86.5	87.5	87.2	86.9	86.7	87.4	88.2	88.3	89.1	87.5	88.0	88.9	88.4	88.6	88.9	89.4	88.2	88.9	88.7	88.4
50-59	83.4	83.6	84.1	81.4	82.0	82.2	82.4	83.1	83.6	83.2	84.5	84.3	85.2	85.4	86.1	85.2	85.0	85.3	85.0	85.5	84.9	85.4
60-64	78.4	77.7	78.4	77.6	76.1	76.4	77.3	76.5	76.9	77.9	78.8	79.6	79.7	81.6	81.1	79.8	81.4	81.6	79.8	81.0	80.5	81.3
65-69	73.0	73.6	73.6	72.1	72.8	71.1	73.1	73.2	73.4	73.9	75.5	77.4	75.5	77.4	76.4	77.0	77.8	76.7	76.2	76.4	76.9	76.7
70-79	66.9	68.1	68.3	65.3	66.3	66.7	66.3	65.5	66.2	67.4	68.4	68.2	68.5	70.0	70.2	70.2	70.9	69.8	69.9	69.5	69.4	69.7
80+	58.5	54.2	63.1	55.0	56.9	58.0	59.0	55.6	55.8	57.7	59.5	59.3	58.5	61.2	61.1	60.4	60.4	59.4	57.5	58.4	57.9	58.0
Male	80.2	80.9	80.4	77.6	77.7	77.1	77.0	76.9	76.8	77.6	78.6	78.0	78.2	79.5	79.2	78.7	79.2	78.8	78.3	78.5	78.1	78.4
Female	81.2	81.0	81.1	78.7	78.8	78.2	78.9	77.4	78.8	78.3	79.0	78.3	78.7	79.4	79.2	78.8	78.9	78.2	77.3	77.3	77.0	77.0
White	79.4	79.6	79.0	76.0	75.6	75.2	75.4	74.4	74.9	75.1	75.9	75.1	75.3	76.5	76.6	76.3	76.5	75.5	75.1	75.4	75.0	74.8
Black	82.7	83.7	84.1	82.1	83.4	82.2	82.7	82.9	83.1	82.8	83.9	83.5	83.9	84.3	83.6	82.7	83.3	83.7	82.4	82.3	81.7	82.3
Other race	81.4	79.7	84.5	80.6	79.4	80.7	80.7	76.3	80.5	84.0	85.1	85.7	84.5	86.2	85.1	82.8	83.1	83.5	81.7	82.8	83.7	85.3
†Hispanic																						
†Non-Hispanic																						
Diabetes	74.4	73.3	72.6	72.3	72.9	72.4	74.0	74.0	75.4	76.2	76.5	76.8	76.9	78.9	78.8	78.2	78.5	77.9	77.0	77.8	77.6	77.9
Hypertension	83.2	81.6	79.7	78.0	77.4	78.2	77.3	75.8	76.4	76.6	77.7	76.9	77.6	77.6	77.6	78.2	78.3	77.2	76.6	76.5	76.3	76.3
Glomerulonephritis	90.8	88.5	87.6	86.3	86.7	86.4	85.0	85.4	85.8	86.0	86.1	85.1	86.9	87.9	86.6	87.0	87.6	87.4	87.6	87.2	87.3	87.6
Other cause	78.9	81.4	83.8	78.5	79.1	77.6	78.9	77.8	77.9	77.8	79.8	78.6	78.7	78.8	78.6	76.5	76.8	77.3	76.3	76.0	74.8	75.2
All	80.6	81.0	80.7	78.1	78.2	77.6	77.9	77.1	77.7	77.9	78.7	78.2	78.4	79.5	79.2	78.8	79.1	78.5	77.8	78.0	77.6	77.8
ADJUSTED																						
0-19	92.1	91.4	91.3	91.5	89.5	87.5	92.1	93.0	90.2	92.6	89.8	90.0	90.8	89.7	93.0	90.3	90.1	92.2	90.2	90.6	88.9	91.3
20-44	87.6	88.7	88.2	88.7	87.8	87.7	88.4	88.0	89.1	88.6	89.6	88.6	89.1	88.7	88.9	87.8	89.3	90.0	89.4	89.8	89.6	89.8
45-64	80.4	80.4	81.2	79.8	79.7	79.9	80.7	81.4	82.1	83.2	83.2	83.2	83.9	85.0	85.0	84.4	84.9	85.4	84.5	85.2	84.8	85.2
65-74	69.7	70.5	72.0	69.0	70.0	69.0	70.3	70.4	71.1	71.8	73.3	73.0	73.5	75.5	74.7	75.4	76.2	75.3	75.1	75.3	75.4	75.3
75+	60.4	62.0	62.0	58.6	60.9	62.0	62.1	59.5	60.1	62.3	63.3	63.5	62.9	64.3	65.2	64.6	65.0	64.0	63.2	63.4	63.2	63.5
Male	74.5	75.4	75.6	73.4	73.8	73.8	74.2	74.2	74.3	75.7	76.9	76.8	77.1	78.6	78.6	78.2	79.2	79.2	78.7	79.3	79.0	79.3
Female	75.8	75.9	77.0	75.4	75.8	75.6	77.0	75.9	77.3	77.5	78.5	78.2	78.7	79.5	79.5	79.4	79.8	79.4	78.6	78.8	78.8	78.9
White	73.3	73.8	74.1	71.9	72.0	72.2	73.1	72.5	73.4	74.4	75.5	75.1	75.6	77.1	77.4	77.4	78.1	77.5	77.3	77.8	77.6	77.6
Black	78.9	79.3	80.0	78.8	80.0	78.9	79.8	80.1	80.2	80.0	81.5	81.3	81.8	82.2	81.6	80.8	81.6	82.2	80.9	80.8	80.4	81.0
Other race	75.7	74.8	79.1	76.8	75.3	77.7	78.7	74.3	78.7	82.6	83.9	84.7	83.4	85.4	84.2	82.7	83.3	83.7	81.9	83.3	84.0	85.4
Diabetes	69.7	68.6	68.5	68.5	69.5	69.1	71.4	71.6	73.2	74.4	75.0	75.6	75.9	78.1	78.1	77.5	78.1	77.8	77.1	78.0	78.0	78.2
Hypertension	80.4	79.5	78.4	77.6	77.2	78.6	78.5	77.4	77.9	78.5	79.7	79.3	79.3	80.2	80.1	80.7	81.1	80.3	80.1	80.1	80.0	80.0
Glomerulonephritis	86.5	84.1	83.4	82.4	83.2	83.5	82.0	82.6	82.7	83.5	83.6	82.7	84.6	85.7	84.7	84.9	85.9	85.7	85.4	85.5	85.5	85.4
Other cause	76.2	78.0	80.8	76.9	77.1	75.7	77.2	76.3	76.3	76.4	78.4	77.7	77.6	77.5	77.4	75.4	75.9	76.7	75.6	74.5	74.9	74.9
All	75.1	75.7	76.3	74.4	74.7	74.7	75.5	75.0	75.8	76.5	77.7	77.5	77.9	79.0	79.0	78.8	79.5	79.3	78.7	79.1	78.9	79.1

Reference cohort is 1996 incident ESRD patients. Overall adjusted survival probabilities are adjusted for age, gender, race, & primary diagnosis. Adjusted survival probabilities for one of the four variables are adjusted for the remaining three. The incident cohorts are determined at the time of ESRD initiation with the 60-day stable modality rule & the 90-day rule. The age of the incident patient is determined as of the date of ESRD initiation. Patients of unknown age or gender, or of age >110 are excluded. Includes residents of the 50 states, the District of Columbia, Puerto Rico, & the Territories; no unknown or foreign states. †CMS began collecting Hispanic ethnicity data in April 1995; cells for years prior to 1996 have therefore been left blank.

Table I.13

Two-year Survival Probabilities: Incident Dialysis Patients

censored at transplant, from day 91 to two years + 90 days, by age, gender, race, ethnicity, & primary diagnosis

UNADJUSTED	1980	1981	1982	1983	1984	1985	1986	1987	1988	1989	1990	1991	1992	1993	1994	1995	1996	1997	1998	1999	2000	
0-4	84.2	89.5	86.1	82.8	84.0	80.2	83.5	80.7	72.2	77.4	72.1	80.7	86.8	79.1	81.9	80.0	82.4	80.4	78.9	79.4	71.5	
5-9	88.9	96.4	91.1	89.6	85.9	89.9	85.2	100.0	100.0	96.8	86.6	95.7	93.9	89.7	96.4	96.8	90.3	97.4	94.3	93.7	95.6	
10-14	95.1	94.7	94.1	96.8	90.9	96.2	95.6	99.0	93.9	96.1	90.8	96.6	90.8	91.7	96.1	93.4	92.4	92.7	96.8	94.6	94.6	
15-19	94.1	90.1	91.7	90.8	93.5	92.0	89.7	93.4	94.6	96.2	94.5	92.9	95.0	92.1	93.4	93.5	90.5	92.9	92.2	92.8	91.4	
20-29	82.7	84.9	84.8	83.2	84.7	81.0	85.4	82.2	86.2	86.2	85.3	85.6	86.9	87.5	86.7	85.6	87.6	88.8	89.4	89.5	86.9	
30-39	78.6	80.0	77.8	80.2	76.2	75.9	76.5	77.4	80.1	79.2	79.8	78.9	80.0	80.7	79.4	79.1	80.2	82.0	81.4	82.2	82.5	
40-49	76.6	75.6	75.4	75.1	75.3	74.3	74.7	76.7	76.5	79.1	75.3	77.5	77.9	77.8	78.4	78.2	79.3	78.5	78.8	78.9	78.9	
50-59	70.5	70.3	70.6	67.7	67.0	66.8	67.1	67.2	68.4	69.6	70.1	70.2	71.4	72.6	73.1	71.7	72.3	72.4	71.5	72.8	72.5	
60-64	63.9	61.4	61.9	61.9	59.1	58.7	60.7	59.4	60.4	61.2	62.0	62.9	63.2	66.0	65.4	64.1	66.0	66.2	64.4	66.3	66.3	
65-69	55.0	56.0	55.3	52.3	55.2	53.0	53.9	55.4	55.9	56.0	56.5	56.7	58.0	60.2	58.9	59.4	60.7	59.0	59.1	59.4	60.8	
70-79	46.6	48.8	49.1	44.4	46.6	47.0	46.5	45.7	46.6	47.8	47.9	48.3	49.2	50.2	50.4	50.7	51.7	49.9	51.0	51.0	50.5	
80+	31.3	34.9	38.6	30.0	36.7	36.0	35.5	33.3	33.5	37.4	37.0	36.2	36.8	37.9	38.7	38.5	38.7	37.1	37.1	37.4	37.3	
Male	65.1	66.1	65.0	61.0	61.5	59.3	60.0	59.6	60.7	61.5	61.8	61.4	62.2	63.9	63.5	63.4	63.6	63.0	63.0	63.5	63.5	
Female	67.5	67.1	66.5	62.9	63.1	62.8	62.2	61.4	62.9	62.8	62.9	62.0	63.1	63.7	63.4	62.9	63.5	62.2	61.7	62.0	61.4	
White	64.1	64.5	63.0	58.8	58.5	57.4	57.1	56.6	57.0	57.4	57.6	56.9	57.8	58.7	58.8	58.6	59.0	57.6	58.1	58.6	58.3	
Black	69.5	70.5	71.1	67.7	69.5	68.0	68.8	68.1	70.5	70.1	70.7	69.7	70.9	72.1	71.1	70.4	71.0	71.0	69.7	69.6	69.4	
Other race	68.6	64.3	70.4	64.8	63.9	62.4	62.6	60.9	65.2	70.3	70.9	73.0	72.6	74.5	72.3	69.1	70.1	70.4	67.9	70.4	71.5	
†Hispanic																					69.5	
†Non-Hispanic																						70.2
Diabetes	55.9	53.5	51.7	53.6	51.5	51.8	53.0	53.8	56.0	57.4	57.1	57.6	58.6	61.0	60.8	60.3	60.9	60.1	59.7	60.9	61.2	
Hypertension	70.5	67.3	65.2	62.1	63.1	61.8	61.1	59.5	61.4	61.3	61.2	60.6	61.6	61.9	62.4	62.9	63.3	61.5	61.3	61.3	61.1	
Glomerulonephritis	79.9	76.9	75.7	73.9	75.1	72.8	71.9	72.1	74.1	73.5	74.1	72.5	74.8	76.6	75.2	76.0	76.4	76.0	77.5	76.7	76.9	
Other cause	64.2	68.6	71.0	62.2	64.3	63.4	64.2	63.3	63.0	64.2	66.2	64.6	65.2	65.2	64.3	62.8	63.4	63.7	63.2	62.9	61.6	
All	66.2	66.6	65.7	61.9	62.2	61.0	61.0	60.5	61.7	62.1	62.3	61.7	62.6	63.8	63.5	63.1	63.6	62.6	62.4	62.8	62.5	
ADJUSTED																						
0-19	87.8	84.9	85.1	83.7	82.9	83.9	81.8	88.1	85.0	88.5	82.5	85.2	87.2	82.1	86.8	84.8	82.5	84.9	83.4	85.7	81.1	
20-44	75.5	78.2	77.2	77.7	76.1	75.2	76.6	76.4	79.2	78.6	79.7	77.8	79.3	79.4	79.1	78.7	79.9	81.5	80.6	81.5	81.4	
45-64	66.3	65.1	66.1	64.7	63.7	63.6	64.7	64.4	65.9	67.5	68.5	68.5	69.7	71.6	71.7	70.9	71.9	72.4	71.4	72.7	72.7	
65-74	50.0	52.0	53.1	48.3	51.5	50.1	50.9	51.8	52.9	53.4	53.9	54.3	55.7	57.1	56.5	57.6	58.6	57.1	57.8	58.2	58.5	
75+	37.8	41.5	40.0	35.7	39.9	40.8	40.2	38.2	38.7	42.0	41.6	41.7	42.1	43.3	44.0	43.4	44.7	42.8	43.5	43.7	43.5	
Male	57.2	58.5	58.4	55.7	56.6	55.4	56.8	56.4	57.7	59.3	60.0	60.1	61.1	63.0	63.0	63.0	64.0	63.9	64.0	64.9	65.1	
Female	60.0	60.1	60.9	58.5	59.4	59.8	59.9	59.9	61.3	62.1	62.7	62.3	63.6	64.2	64.3	64.2	65.2	64.4	64.1	64.5	64.4	
White	55.7	56.8	56.5	53.8	54.4	54.3	54.8	55.0	55.8	57.4	57.8	57.8	59.0	60.2	60.7	61.0	62.1	61.3	61.9	62.7	62.6	
Black	63.8	63.9	64.9	62.8	64.5	63.3	64.7	64.0	66.3	66.1	67.1	66.5	67.7	69.1	68.2	67.7	68.6	68.7	67.5	67.4	67.6	
Other race	60.8	57.7	62.3	59.4	58.7	58.8	60.2	58.6	63.1	68.6	69.3	71.8	71.2	73.4	71.3	69.2	70.6	71.1	68.5	71.5	72.1	
Diabetes	50.0	47.8	46.9	49.0	47.6	48.1	49.9	51.0	53.5	55.3	55.4	56.3	57.5	60.0	60.0	59.6	60.7	60.3	60.0	61.4	61.9	
Hypertension	66.5	64.7	63.8	62.0	63.3	63.1	63.3	62.3	63.9	64.4	64.7	64.5	65.3	66.0	66.4	67.0	67.7	66.3	66.7	66.7	66.7	
Glomerulonephritis	72.4	70.0	69.5	68.3	70.1	68.9	68.1	68.4	69.8	70.0	70.7	69.1	71.5	73.2	72.4	72.8	73.8	73.3	74.2	74.1	74.3	
Other cause	60.7	64.0	66.9	60.5	62.2	61.3	62.4	61.7	61.3	62.8	64.5	63.3	64.0	63.8	63.1	61.8	62.5	63.2	62.4	62.5	61.5	
All	58.5	59.3	59.6	57.0	57.9	57.5	58.3	58.1	59.4	60.7	61.3	61.1	62.3	63.6	63.6	63.6	64.6	64.1	64.1	64.7	64.8	

Reference cohort is 1996 incident ESRD patients. Overall adjusted survival probabilities are adjusted for age, gender, race, & primary diagnosis.

Adjusted survival probabilities for one of the four variables are adjusted for the remaining three. The incident cohorts are determined at the time of ESRD initiation with the 60-day stable modality rule & the 90-day rule.

The age of the incident patient is determined as of the date of ESRD initiation.

Patients of unknown age or gender, or of age > 110 are excluded. Includes residents of the 50 states, the District of Columbia, Puerto Rico, & the Territories.

†CMS began collecting Hispanic ethnicity data in April 1995; cells for years prior to 1996 have therefore been left blank.

Table I.14

Five-year Survival Probabilities: Incident Dialysis Patients

censored at transplant, from day 91 to five years + 90 days, by age, gender, race, ethnicity, & primary diagnosis

UNADJUSTED	1980	1981	1982	1983	1984	1985	1986	1987	1988	1989	1990	1991	1992	1993	1994	1995	1996	1997	
0-4	84.2	78.1	86.1	75.3	69.8	69.1	71.1	70.1	66.9	70.5	58.4	70.3	73.8	66.9	72.5	72.2	67.8	69.4	
5-9	88.9	96.4	69.4	81.5	85.9	74.2	79.1	89.5	92.9	82.9	77.7	95.7	79.8	79.2	89.3	81.8	87.6	97.4	
10-14	82.4	79.1	87.7	94.8	84.6	91.3	83.8	86.6	76.2	86.3	84.6	84.1	82.6	83.6	81.5	86.2	85.8	85.8	
15-19	88.4	81.1	80.6	86.1	85.5	73.8	77.3	82.7	79.0	80.4	86.2	84.2	87.5	80.5	83.8	85.3	82.0	84.7	
20-29	74.0	68.6	69.3	65.9	64.0	61.5	68.1	65.0	70.7	67.0	69.1	69.7	70.8	72.2	71.8	72.4	74.2	74.5	
30-39	60.0	60.1	54.5	56.5	54.8	52.7	53.1	51.3	57.7	58.1	57.2	57.1	57.9	59.9	58.6	58.6	59.9	61.9	
40-49	52.7	50.7	50.4	47.0	49.3	47.9	47.9	48.7	50.8	48.3	50.5	48.8	49.7	50.6	51.1	52.4	51.6	53.0	
50-59	40.3	40.7	39.7	37.2	36.1	34.9	36.5	37.3	37.0	36.8	37.3	38.9	38.3	40.4	40.2	40.1	40.0	40.9	
60-64	31.8	31.3	29.7	29.4	26.9	26.6	28.1	27.0	28.8	28.2	29.3	29.4	29.7	31.4	31.6	30.0	31.5	33.0	
65-69	23.4	24.9	24.2	20.7	22.4	22.4	22.0	23.0	23.0	22.8	22.9	21.9	23.9	24.2	25.0	24.5	25.3	24.5	
70-79	16.0	16.2	17.2	14.1	15.4	15.8	15.1	15.8	15.8	16.3	15.8	16.2	16.1	16.9	16.7	17.3	18.1	17.2	
80+	8.5	7.8	7.9	6.5	8.1	8.3	7.8	8.1	7.1	9.2	8.8	7.9	7.8	8.4	8.5	9.1	9.3	8.4	
Male	37.0	35.7	34.4	30.1	30.0	28.3	29.0	29.2	30.2	30.4	30.3	30.2	30.1	31.8	31.9	32.3	32.2	31.9	
Female	38.9	39.5	36.8	33.2	32.9	32.1	31.6	31.1	32.2	30.8	31.1	30.4	30.9	31.4	31.2	30.9	31.0	30.9	
White	36.3	34.4	32.2	27.9	27.6	26.2	25.6	25.3	25.2	24.8	24.6	24.2	24.4	25.2	25.5	25.2	25.5	24.7	
Black	40.8	43.4	41.7	37.7	38.8	37.6	39.0	38.6	41.7	40.2	41.2	40.5	40.7	41.8	41.3	42.0	41.5	42.2	
Other race	35.9	34.3	41.9	37.7	31.2	30.3	31.2	35.7	36.7	40.0	39.7	40.7	42.0	43.8	42.1	37.9	39.5	41.4	
†Hispanic																		38.7	38.1
†Non-Hispanic																		30.7	30.5
Diabetes	25.6	22.5	19.5	20.4	19.2	18.8	20.8	21.1	22.9	22.1	22.4	22.9	23.7	25.1	25.5	25.1	25.5	25.6	
Hypertension	43.3	38.4	35.9	33.3	32.5	31.5	30.8	30.0	31.8	30.9	31.5	30.1	30.5	30.7	31.2	32.6	32.7	32.0	
Glomerulonephritis	55.8	50.9	47.9	45.4	44.6	41.1	41.5	42.8	44.5	44.4	44.7	44.9	45.7	48.0	47.1	48.8	48.6	48.4	
Other cause	35.4	39.8	41.1	32.3	35.1	34.8	34.7	35.0	34.7	36.5	36.5	36.4	35.8	37.4	36.6	36.4	36.9	37.7	
All	37.9	37.5	35.5	31.6	31.4	30.1	30.2	30.1	31.2	30.6	30.7	30.3	30.5	31.6	31.5	31.6	31.6	31.4	
ADJUSTED																			
0-19	77.8	69.7	70.9	77.2	72.5	63.6	66.3	71.9	66.3	69.6	70.9	72.2	74.6	66.6	71.8	72.8	70.9	74.6	
20-44	56.5	55.8	53.4	52.2	52.7	50.1	53.2	51.7	55.6	55.1	56.1	54.8	55.9	56.7	57.0	57.0	57.8	59.3	
45-64	34.6	34.4	34.4	32.7	31.7	31.3	33.1	33.2	34.5	34.6	35.7	36.9	36.8	39.0	39.3	39.4	40.1	41.6	
65-74	18.8	20.1	20.7	17.2	19.0	19.3	18.8	20.2	20.5	20.8	21.0	20.4	21.9	22.3	22.8	23.1	24.1	23.3	
75+	10.7	11.1	11.1	8.8	10.5	10.9	10.9	10.9	10.3	12.2	11.0	11.7	10.7	11.7	11.5	12.4	13.1	12.3	
Male	29.3	28.7	28.9	26.1	26.7	26.4	27.6	27.8	28.6	29.8	29.7	30.3	30.4	32.1	32.4	33.0	33.9	33.9	
Female	31.2	32.4	31.7	29.8	30.5	30.4	30.8	31.2	32.0	31.7	32.3	32.2	33.0	33.4	33.8	33.9	34.7	34.9	
White	28.3	27.4	27.2	24.9	25.6	25.4	25.8	26.1	26.4	27.3	27.1	27.4	28.0	29.1	29.7	30.0	31.2	30.8	
Black	34.0	35.7	34.6	32.5	33.6	33.0	34.8	34.7	36.9	35.9	37.2	37.2	37.3	38.4	38.1	39.0	38.9	39.7	
Other race	28.6	29.3	33.3	33.2	27.7	29.2	30.9	34.8	35.5	39.6	38.8	41.1	41.7	43.4	42.3	39.4	41.6	43.5	
Diabetes	21.5	19.0	17.4	18.1	17.7	17.7	19.6	20.3	21.8	21.7	22.0	22.9	23.8	25.2	25.8	25.6	26.5	26.6	
Hypertension	39.4	36.3	35.8	34.7	34.5	34.7	35.0	34.9	36.0	35.9	36.8	36.1	36.1	36.7	37.0	38.2	38.9	38.4	
Glomerulonephritis	45.7	42.9	41.5	40.2	40.6	38.7	39.0	40.0	40.9	41.6	41.5	42.4	42.6	44.3	44.3	44.9	45.7	45.3	
Other cause	32.6	35.6	37.5	31.5	34.2	34.0	34.4	34.6	34.1	36.3	35.6	36.0	35.6	36.8	36.3	36.0	36.7	37.8	
All	30.2	30.4	30.2	27.8	28.5	28.3	29.1	29.4	30.2	30.7	30.9	31.2	31.6	32.7	33.0	33.4	34.3	34.3	

Reference cohort is 1996 incident ESRD patients. Overall adjusted survival probabilities are adjusted for age, gender, race, & primary diagnosis. Adjusted survival probabilities for one of the four variables are adjusted for the remaining three.

The incident cohorts are determined at the time of ESRD initiation with the 60-day stable modality rule & the 90-day rule. The age of the incident patient is determined as of the date of ESRD initiation.

Patients of unknown age or gender, or of age >110 are excluded. Includes residents of the 50 states, the District of Columbia, Puerto Rico, & the Territories.

†CMS began collecting Hispanic ethnicity data in April 1995; cells for years prior to 1996 have therefore been left blank.



Table I.15

Ten-year Survival Probabilities: Incident Dialysis Patients*censored at transplant, from day 91 to ten years + 90 days, by age, gender, race, & primary diagnosis*

UNADJUSTED	1980	1981	1982	1983	1984	1985	1986	1987	1988	1989	1990	1991	1992
0-4	84.2	67.0	68.9	62.8	61.0	37.8	71.1	62.3	46.8	62.7	46.0	66.4	66.4
5-9	88.9	74.4	52.0	81.5	85.9	59.3	79.1	78.3	92.9	58.1	64.7	42.5	73.2
10-14	64.0	62.9	72.0	84.8	65.6	86.5	64.7	86.6	54.6	67.6	59.7	73.6	70.1
15-19	80.6	64.2	70.5	74.3	66.0	60.8	59.5	58.7	66.5	69.8	67.6	70.8	65.3
20-29	54.6	48.5	49.0	47.6	46.1	46.7	47.5	45.8	48.6	46.2	48.1	47.4	50.0
30-39	38.8	37.2	32.7	35.1	33.8	32.2	31.3	30.5	32.8	34.9	34.0	34.1	34.6
40-49	26.1	24.3	23.6	23.0	25.4	22.9	21.9	22.9	24.8	21.1	22.6	21.2	22.8
50-59	13.4	14.2	14.4	12.2	12.2	12.9	12.2	12.3	11.7	11.5	11.3	12.5	11.8
60-64	8.2	8.1	6.7	7.9	7.4	7.7	7.4	6.8	7.4	6.6	6.5	7.3	7.2
65-69	4.8	5.4	4.3	4.8	5.2	5.9	4.8	4.4	4.5	4.3	4.7	4.2	4.5
70-79	2.7	2.4	2.9	2.4	3.0	2.9	2.4	2.8	2.5	2.3	2.0	1.9	2.2
80+	2.5	2.1	3.3	0.6	2.0	1.2	1.1	1.2	0.6	0.9	0.4	0.8	0.6
Male	14.2	13.1	12.3	11.0	11.4	10.7	10.6	10.3	10.3	10.0	10.4	10.0	10.3
Female	16.1	16.0	13.7	12.6	12.3	11.9	10.6	10.2	11.1	10.1	9.4	9.6	9.5
White	14.7	12.8	11.4	9.9	9.9	9.1	8.1	8.1	7.6	6.8	6.9	6.8	6.8
Black	16.1	17.4	15.8	14.9	15.0	15.4	14.8	14.1	16.1	15.5	14.7	14.8	15.0
Other race	13.2	14.8	17.9	15.4	14.9	12.0	14.3	13.5	14.1	14.8	16.3	15.7	16.3
Diabetes	7.7	5.9	5.0	5.0	4.9	4.9	4.7	4.7	5.2	4.5	4.7	4.6	4.8
Hypertension	18.0	15.2	12.4	12.1	11.8	11.1	10.4	9.5	10.7	10.2	9.7	9.6	10.1
Glomerulonephritis	31.0	23.6	19.7	19.5	20.5	18.9	18.4	18.3	18.8	19.2	19.4	18.8	20.9
Other cause	12.9	15.3	16.5	13.2	14.2	14.7	14.1	14.4	14.4	14.4	15.0	15.6	14.9
All	15.1	14.5	13.0	11.8	11.8	11.3	10.6	10.3	10.7	10.0	9.9	9.8	9.9
ADJUSTED													
0-19	64.7	50.0	54.2	62.8	51.4	48.1	49.5	51.5	50.5	54.4	49.5	56.0	53.4
20-44	34.1	31.4	29.3	30.3	30.9	29.8	29.8	28.8	30.5	30.9	31.1	30.4	31.4
45-64	10.5	10.7	10.8	10.0	10.3	10.5	10.6	10.6	10.9	10.3	10.7	11.6	11.6
65-74	3.4	3.6	3.4	3.5	4.1	4.6	3.8	3.8	3.7	3.7	3.8	3.5	3.9
75+	1.8	2.0	2.4	1.1	1.9	1.6	1.4	1.7	1.5	1.4	0.8	1.2	1.1
Male	10.9	10.4	10.7	10.0	10.8	11.2	11.1	10.9	10.6	10.7	11.1	11.2	11.4
Female	12.5	12.9	12.3	11.9	12.5	12.6	11.7	12.0	12.6	12.1	11.7	12.2	12.4
White	11.1	10.3	10.3	9.6	10.4	10.5	10.0	10.2	9.9	9.7	9.9	10.1	10.4
Black	12.3	13.1	12.4	12.2	12.8	13.3	12.8	12.7	13.8	13.2	13.0	13.4	13.5
Other race	10.4	13.0	14.5	14.7	13.8	13.1	15.4	14.9	14.6	16.4	16.6	17.8	18.0
Diabetes	6.4	5.3	5.0	5.0	5.2	5.4	5.0	5.3	5.5	4.9	5.3	5.4	5.6
Hypertension	16.9	15.5	14.3	14.6	14.8	14.8	14.5	14.3	14.5	14.4	13.9	14.1	14.6
Glomerulonephritis	22.7	18.8	17.3	17.1	19.0	18.9	17.9	17.6	17.6	18.1	17.9	18.0	19.3
Other cause	12.9	14.3	15.7	13.7	15.1	15.7	15.1	15.3	15.0	15.4	15.3	16.2	15.6
All	11.6	11.5	11.4	10.8	11.6	11.8	11.3	11.4	11.5	11.3	11.3	11.6	11.8

Reference cohort is 1996 incident ESRD patients.

Overall adjusted survival probabilities are adjusted for age, gender, race, & primary diagnosis.

Adjusted survival probabilities for one of the four variables are adjusted for the remaining three.

The incident cohorts are determined at the time of ESRD initiation with the 60-day stable modality rule & the 90-day rule.

The age of the incident patient is determined as of the date of ESRD initiation.

Patients of unknown age or gender, or of age >110 are excluded. Includes residents of the 50 states, the District of Columbia, Puerto Rico, & the Territories.

